JAMA : the journal of the American Medical Association
-
Randomized Controlled Trial Multicenter Study
Survival without disability to age 5 years after neonatal caffeine therapy for apnea of prematurity.
Very preterm infants are prone to apnea and have an increased risk of death or disability. Caffeine therapy for apnea of prematurity reduces the rates of cerebral palsy and cognitive delay at 18 months of age. ⋯ Neonatal caffeine therapy was no longer associated with a significantly improved rate of survival without disability in children with very low birth weights who were assessed at 5 years.
-
Editorial Comment
Neuroprotection for premature infants?: another perspective on caffeine.